InvestorsHub Logo
Followers 85
Posts 12714
Boards Moderated 0
Alias Born 10/12/2010

Re: cjgaddy post# 223044

Wednesday, 07/01/2015 10:51:59 PM

Wednesday, July 01, 2015 10:51:59 PM

Post# of 346426

Sep6-9: IASLC’s 16th World Conf. on Lung Cancer”, Denver wclc2015.iaslc.org
…Peregrine Exhibiting, Booth #1724 (KOL/SAB Dr. David Carbone will be Pres. of IASLC eff. 9-2015)



William D. Travis sits on the BOD at IASLC (2013-2016) so I would say soon to be President at IASLC David Carbone has had many a words with Dr. Travis from Sloan Kettering before Peregrines and MSK's collaboration. Who knows, lots of money and trials are served directly out of IASLC and MSK just may benefit big time from this collaboration.

https://www.iaslc.org/membership/member-directory/william-d-travis

"Bavituximab is a first-in-class phosphatidylserine (PS)-targeting monoclonal antibody that is the cornerstone of a broad clinical
pipeline."
-- Big Pharmas nightmare... unless they are fortunate enough to have The Bavi Edge!

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent CDMO News